Cheapest Place to Get Wegovy in 2026: Every Legitimate Path Ranked by Out-of-Pocket Cost

The first time people see Wegovy's retail price — $1,349 for a four-week supply — many assume the drug is simply out of reach. That number is real. It is also almost never what a patient in 2026 actually pays.

Novo Nordisk has restructured its pricing, a federal Medicare program launches July 1, and a handful of telehealth platforms have made the drug easier to access than it was two years ago. The range of legitimate out-of-pocket costs now spans from $25 to $499 per month, depending on your insurance status and which door you walk through. This article maps every door.

The complete 2026 price map: all legitimate paths ranked

Here is the landscape as of May 2026. Prices are for brand-name, FDA-approved Wegovy only — not compounded semaglutide.

The $1,349 retail sticker is included for completeness. It is the price you pay if you walk up to a retail counter without any savings mechanism applied. No informed patient should pay it.

Path 1: Commercial insurance + the Wegovy Savings Offer

If your employer-sponsored or marketplace insurance plan covers Wegovy, the Novo Nordisk Savings Offer can take your monthly copay to as little as $25, subject to a maximum manufacturer saving of $100 per month. The savings card works on top of whatever your insurance pays — it is a bridge between the negotiated rate and your wallet.

Eligibility: You need a valid Wegovy prescription, commercial (non-government) insurance, and US residency. The offer is closed to Medicare, Medicaid, TRICARE, the VA, and any other federal or state program.

How to enroll: Visit wegovy.com and complete the savings form, or text SAVE to 83757. Alternatively, your prescriber's office can print the card from novomedlink.com. Take the activated card to any participating retail pharmacy.

The catch most people hit: Coverage for anti-obesity drugs is still not universal. A significant share of employer plans exclude weight-management medications from formulary. If your plan does not list Wegovy as covered, the savings card's $25 floor does not apply — you are paying cash, in which case Path 3 (NovoCare) is the lower-cost option.

If you are unsure whether your plan covers Wegovy, use NovoCare's coverage check tool before assuming your copay will be $25.

Path 2: Medicare GLP-1 Bridge — the new $50 option

Starting July 1, 2026, Medicare beneficiaries enrolled in a Part D plan or Medicare Advantage with prescription coverage will have access to Wegovy at a $50 per month copay through the CMS Medicare GLP-1 Bridge — a federal demonstration program running through December 31, 2027.

The program covers all formulations of Wegovy, according to a Novo Nordisk press release and CMS documentation. The $50 copay does not increase with dose escalation — someone at 2.4 mg pays the same $50 as someone at 0.25 mg. However, the $50 does not count toward the Part D deductible or the $2,100 annual out-of-pocket cap, and Low-Income Subsidy cost-sharing will not apply to this program according to the KFF analysis.

To qualify: Your prescriber submits prior authorization attesting that you are prescribed Wegovy for weight reduction and that you meet clinical BMI criteria. You do not need to enroll separately — Part D sponsors participate automatically. Talk to your prescriber now if you want to be ready at the July 1 launch.

This path has been absent from the conversation for years, because Medicare historically did not cover obesity medications. That changes in six weeks.

Path 3: NovoCare Pharmacy — the best cash-pay option right now

For anyone without insurance coverage, the cleanest path is NovoCare Pharmacy, Novo Nordisk's own direct-to-patient pharmacy.

Current pricing (as of May 2026):

• $199/month — introductory rate for new patients on the 0.25 mg or 0.5 mg starter doses; available for the first two monthly fills, extended through June 30, 2026
• $349/month — standard rate for any Wegovy pen from 0.25 mg through 2.4 mg
• $399/month — Wegovy HD 7.2 mg pen
• $149/month — Wegovy pill (1.5 mg and 4 mg daily tablet)

All pricing sourced from the NovoCare savings page (verified May 2026). Free shipping is included. The $349 price holds across every dose — you do not pay more as you escalate from 0.5 mg to 2.4 mg, which differs from most insurance billing.

How to set it up: Ask your prescriber to send the prescription directly to NovoCare, or enroll at NovoCare.com and transfer an existing prescription. There is no separate card to activate — the cash-pay pricing applies automatically to uninsured patients. See our NovoCare Wegovy enrollment walkthrough for the step-by-step process.

Note the expiry on the $199 intro offer: if you are starting your first fill after June 30, 2026, you move straight to $349.

Why $349, not $499?

Until November 2025, NovoCare's standard cash-pay price was $499 per month. Novo Nordisk dropped it to $349 — a cut of roughly 30% — in a November 17, 2025 announcement that coincided with expanded pricing availability at retail pharmacies. Reddit threads from that period capture real patients describing the change: one user in r/Semaglutide summarised the new setup bluntly: "There is a coupon on the Wegovy website for cash pay patients. The highest dose price is $349." The drop was Novo's response to narrowing cost parity with compounded semaglutide and growing Congressional attention to GLP-1 list prices.

Path 4: The Wegovy pill — lower entry cost, different form factor

Oral Wegovy (semaglutide) received FDA approval in late 2025, and the pill carries a meaningfully lower price than the injectable pen.

Tablet pricing through NovoCare:

• $149/month — 1.5 mg and 4 mg doses (4 mg offer available through August 31, 2026, then increases to $199/month)
• $199/month — higher titration doses
• $299/month — maintenance doses (9 mg, 25 mg)

The pill is taken daily instead of weekly and has different absorption pharmacology than the subcutaneous injection. Whether the pill is appropriate is a clinical conversation with a prescriber. For cost purposes: $149/month is currently the lowest available price point for any brand-name semaglutide product approved for weight management.

Path 5: Costco + Sesame telehealth

In October 2025, Costco partnered with Novo Nordisk to offer Wegovy and Ozempic to members at roughly $499 per month — approximately half the standard retail list price at the time. Costco members access the offer through Sesame Care's telehealth platform.

At $499, this is no longer the cheapest route since NovoCare dropped to $349. But it remains useful for Costco members who want in-store pharmacy pickup rather than mail delivery, or who prefer the Sesame Care prescribing platform for ongoing support. A Costco Gold Star membership costs $65/year, which adds roughly $5.40/month to the effective total.

Path 6: Telehealth platforms — convenient, but add platform fees

Online prescribing platforms — Ro, Hims, PlushCare, LifeMD, Noom Med — handle the prescription and, in some cases, ship the medication directly. For brand-name Wegovy, they layer a monthly platform subscription on top of the drug cost.

Representative 2026 pricing from Medical News Today's platform comparison:

• Ro Body: ~$45 first month, ~$145/month after (subscription only; drug cost separate)
• Hims: ~$39 first month, ~$149/month ongoing subscription
• PlushCare: $19.99/month subscription
• Noom Med: ~$69 first month, ~$99/month ongoing

The drug itself, if prescribed as brand-name Wegovy, still runs $349 through NovoCare. These platforms charge for the clinical layer on top. For patients who value coaching, nutritional support, or convenience of a single integrated app, the premium may be worth it. For pure cost comparison, NovoCare direct is lower by the platform fee amount every month.

Some platforms offer the Wegovy pill starting at $149/month all-in, which can undercut the pen-plus-platform equation.

What does "cheapest" actually look like in practice?

Three common situations from r/Semaglutide and r/loseit threads illustrate why the "cheapest" answer is patient-specific.

Situation A — Insurance dropped coverage mid-treatment. One r/Semaglutide user described a scenario many readers will recognise: "My Wegovy is waiting at CVS at $1,015. It was a zero copay in December." Their plan changed its deductible structure mid-year. The correct move in this case is to stop filing through insurance and switch to NovoCare cash pay at $349, using the cash route explicitly. Multiple commenters in that thread confirmed: "You have to let the pharmacy know not to bill through insurance."

Situation B — Starting fresh with no coverage. For a new patient with no insurance and no prior fills, the $199 intro offer at NovoCare covers the 0.25 mg and 0.5 mg starter period — typically two months before your prescriber evaluates escalation. That is six weeks of lower cost before the $349 standard rate applies.

Situation C — Medicare and frustrated. Before the Bridge program, Medicare patients were largely excluded from both the savings card and meaningful coverage. From July 1, that calculus changes. A patient currently paying $349/month cash who is also on Medicare Part D should contact their prescriber in June about triggering the Bridge enrollment before the program launches.

What to watch out for: the gray and the sketchy

Some Reddit discussion about cost points toward providers offering compounded semaglutide. Our compounded vs brand semaglutide guide covers the regulatory status and quality differences in full detail. A few key facts:

• The FDA declared the nationwide semaglutide shortage resolved on February 21, 2025.
• Most 503A and 503B compounders lost their legal authority to produce bulk compounded semaglutide by May 2025.
• What remains is a smaller segment of compounders making personalised preparations under specific 503A rules. Prices vary, quality control varies, and the legal landscape is still in flux.

One commenter in r/Semaglutide noted: "I tried to help you legally and safely get a far cheaper price but my response was deleted as I didn't realize the rules on this sub." That comment reflects the tension in these communities: members actively warn each other about the risk of unregulated products, while also acknowledging that $349/month remains unaffordable for many.

The practical bottom line on safety: if an offer looks substantially cheaper than $349 for injectable semaglutide with no telehealth layer visible, you are almost certainly looking at compounded semaglutide, not brand-name Wegovy. Evaluate accordingly and consult a pharmacist or prescriber on any product whose regulatory status you cannot verify.

The Novo Nordisk PAP: the one gap in the safety net

Many patients assume Novo Nordisk's Patient Assistance Program — which provides free Ozempic and insulin products to uninsured patients under 400% of the Federal Poverty Level — also covers Wegovy. It does not. As of May 2026, Wegovy and Saxenda are both excluded from the PAP. The program covers Ozempic (semaglutide 2 mg for diabetes), Rybelsus, and various insulins — not the obesity-indicated formulations.

Independent foundations, such as the Patient Advocate Foundation and those listed on NeedyMeds.org, provide separate co-pay assistance for anti-obesity medications in some cases. Availability and income caps change frequently; check current listings directly.

Side-by-side: the five-number cheat sheet

For a cash-paying patient deciding where to start today:

Frequently asked questions

See the frontmatter FAQ block above for eight detailed answers. Additional context on the questions most commonly seen in patient forums:

"Is there a GoodRx coupon that beats $349?" GoodRx has historically listed Wegovy coupons, but the effective prices at retail pharmacies often run higher than NovoCare's direct price after the coupon is applied. Always compare the GoodRx coupon price at your specific pharmacy against NovoCare before assuming the coupon wins. For the full savings-card mechanics, see our GLP-1 savings card guide. If you are not yet prescribed, our how to get a GLP-1 prescription guide covers the process from first appointment to filled Rx.

"Will the $349 price last?" NovoCare has extended its introductory $199 offer twice already (from March to June 2026). The $349 standard rate is not legally guaranteed; Novo Nordisk could revise it. There is no binding multi-year commitment. Check NovoCare.com before assuming the price holds at your next fill.

"Can I get Wegovy cheaper by going to Canada or Mexico?" Importation of prescription drugs for personal use is a grey area under US law. Wegovy is available in several other markets, but dose formulations and approval statuses differ. This article covers US legal channels only; cross-border importation carries legal and safety risks outside our editorial scope.

The cheapest place to get Wegovy in May 2026 — for a cash-paying, uninsured adult — is NovoCare Pharmacy at $349 per month. For a commercially insured patient whose plan covers the drug, the Wegovy Savings Offer brings that to $25. For a Medicare beneficiary, July 1 is the date to mark.

The $1,349 retail price is a real number. It just describes the wrong path.